SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jack Doerr who wrote (414)4/11/2000 7:43:00 PM
From: LemurHouse   of 656
 
Doctors can and do use drugs for "off label" indications, and Enbrel is certainly being used already for earlier stage RA, etc. But nowhere near the extent to which it will be used when formal FDA approval is forthcoming for the expanded labeling. (Assuming that such approval will in fact be forthcoming. Seems to be little doubt at this point, but why tempt fate?) Doctors will feel much less inhibited, and just as importantly, the insurance companies will feel more compelled to cover the Rx. So the FDA approval is in fact quite important.

I'm sure IMNX was on CNBC all day today, but I only saw the 5:00 edt interview of the COO by Maria Bartiromo. Bartiromo's interview was horrendously bad, she having little to no understanding of the issues, esp the fact that Enbrel is clearly the treatment of choice for RA.

AD
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News